The clinical evidence for psychedelic-assisted therapy in veteran PTSD reached a turning point between 2023 and 2026. The VETS Inc. study published by Davis and colleagues in Nature Medicine reported that 93.2 percent of 86 US special operations veterans showed clinically significant improvement after a single ibogaine and 5-MeO-DMT protocol (Davis et al., Nature Medicine, 2023). Stanford's follow-up by Cherian and colleagues reported 88 percent PTSD remission in a related cohort (Cherian et al., Nature Medicine, 2024). MAPP2 reported 71.2 percent of MDMA participants no longer meeting PTSD criteria. The Trump administration's April 2026 executive order accelerated the federal pathway in response.
The scale problem these numbers address is not abstract. Roughly 7 to 8 percent of US veterans meet criteria for PTSD at some point in their lives according to RAND and the National Comorbidity Survey Replication. The VA's 2023 National Veteran Suicide Prevention Annual Report documented an average of approximately 17 to 22 veteran suicides per day depending on the analysis methodology. Standard first-line PTSD treatments produce response rates that, while clinically meaningful, leave a substantial population without remission. Veterans, their clinicians, and increasingly their elected officials have noticed.
If you've read our jurisdictional guide to legal psychedelic therapy in 2026, this article is the veteran-specific operational map alongside it. Most of the founders I work with in integration have some kind of high-pressure background, and a meaningful portion of them are veterans transitioning into entrepreneurship. The mechanism by which a single supervised session restructures trauma responses is the same in both contexts, but the access pathways, the screening considerations, and the documentation implications differ. This article covers both.
- VETS Inc. study (Davis, Nature Medicine, 2023) reported 93.2 percent of 86 special operations veterans showed clinically significant improvement after one ibogaine plus 5-MeO-DMT protocol in Mexico.
- Stanford's Cherian follow-up reported 88 percent PTSD remission post-ibogaine (Stanford Medicine, 2024).
- MAPP2 Phase 3 trial reported 71.2 percent of MDMA-assisted therapy participants no longer met PTSD criteria at study endpoint (Mitchell, Nature Medicine, 2023).
- The Department of Veterans Affairs announced a nine-site psilocybin clinical trial network for veteran PTSD, with active enrollment in 2025 and 2026.
- The Trump administration's April 2026 executive order directed the FDA to accelerate review of psilocybin, MDMA, and ibogaine for veteran mental health applications.
How Big Is the Veteran Mental Health Problem in 2026?
An estimated 7 to 8 percent of US veterans meet criteria for PTSD at some point in their lifetime according to the RAND Corporation's analysis of veteran behavioral health data (RAND, 2008-2023 longitudinal series). The Department of Veterans Affairs 2023 National Veteran Suicide Prevention Annual Report documented an average of approximately 17 to 22 veteran suicides per day, depending on the analytic methodology used to attribute deaths. The combination of high prevalence and high mortality has reshaped policy attention.
The prevalence figure varies by service era. Vietnam-era veterans show higher lifetime PTSD rates than the overall veteran population. Post-9/11 combat veterans, particularly those with multiple deployments and special operations exposure, also show elevated rates. Special operations veterans in particular often combine PTSD with traumatic brain injury, blast exposure, and operator-specific moral injury. This combined profile is precisely the population the VETS Inc. ibogaine study recruited and that has driven the most striking response rates in the literature.
Standard first-line PTSD treatments produce real but incomplete remission. SSRIs and SNRIs help a portion of patients. Trauma-focused psychotherapies including prolonged exposure and cognitive processing therapy produce meaningful improvement in many but leave a substantial nonresponse population. The treatment-resistant cohort is large enough, and the suicide rate is high enough, that the field has moved on the psychedelic question faster than it would in a lower-mortality condition. The data emerging from MDMA, ibogaine, and psilocybin trials substantially exceed those standard response rates in head-to-head comparisons within the trials themselves.
What Did the VETS Inc. Ibogaine Study Actually Show?
Davis and colleagues, publishing in Nature Medicine in January 2024, followed 86 US special operations veterans through a single ibogaine plus 5-MeO-DMT protocol at a licensed Mexican clinic and reported 93.2 percent showing clinically significant improvement at one-month follow-up (Davis, Nature Medicine, 2024). The cohort was severe by any standard: high rates of traumatic brain injury, combat-related PTSD, depression, and disability. The study was naturalistic rather than randomized, but the effect size and the population characteristics were striking.
The Stanford Cherian Follow-Up
Cherian and colleagues at Stanford published a related analysis in Nature Medicine focused on the traumatic brain injury and PTSD overlap. The Stanford team reported 88 percent of participants no longer meeting PTSD diagnostic criteria at one-month follow-up. They also reported substantial improvements in functional disability measures, depression scores, and anxiety scores. The combination of PTSD remission with measurable functional gains is the part that distinguishes psychedelic protocols from typical PTSD treatment trajectories.
Why the Cohort Composition Matters
The VETS Inc. cohort is the population most likely to show floor effects in conventional treatment. Special operations veterans have, on average, the longest deployment histories and the highest combat exposure rates of any veteran subgroup. The fact that 93.2 percent showed clinically significant improvement after a single supervised protocol in a population that conventional trials would consider treatment-resistant is genuinely unusual in the trauma literature. Ibogaine carries cardiac risks that require careful pre-screening, and the protocol is not appropriate for every patient, but the signal in those who completed it was clear.
Davis and colleagues, publishing in Nature Medicine in 2024, followed 86 US special operations veterans through a single ibogaine plus 5-MeO-DMT protocol in Mexico and reported that 93.2 percent showed clinically significant improvement at one-month follow-up, with the Stanford team's Cherian analysis reporting 88 percent PTSD remission in a related cohort (Davis et al., Nature Medicine, 2024; Cherian et al., Nature Medicine, 2024). These results substantially exceed standard veteran PTSD treatment response rates and have shaped 2026 policy attention.
What Do the MDMA Phase 3 Trials Show for Veterans?
The MAPP1 Phase 3 trial reported 67 percent of MDMA-assisted therapy participants no longer met PTSD criteria at study endpoint, and MAPP2 reported 71.2 percent (Mitchell, Nature Medicine, 2023). The MAPP1 publication appeared in Nature Medicine in 2021, and the MAPP2 confirmatory trial published in 2023. A meaningful portion of both trial cohorts were military veterans, although the trials enrolled broadly rather than veteran-specifically. The MDMA evidence base for PTSD is now the most clinically replicated of any psychedelic protocol.
The FDA issued a Complete Response Letter to Lykos Therapeutics in August 2024, requesting additional Phase 3 evidence before approval. The CRL did not invalidate the trial results, it raised methodological questions specific to the design and the functional unblinding inherent in psychedelic trials. The path forward under the Trump April 2026 executive order is now under active review. Expanded-access MDMA protocols at specific US clinical sites remain available for veterans through Department of Defense and academic partnerships, with the Veterans Affairs system referencing several of these sites in its post-2024 access planning documentation.
For veterans considering MDMA-assisted therapy in 2026, the legal options are expanded-access sites in the United States, Australia under the TGA Authorised Prescriber scheme that activated July 2023, or Switzerland under Section 8(5) compassionate use. The Australian pathway has become operationally significant for international veteran clients with documented treatment-resistant PTSD. The Swiss pathway is narrower and typically requires longer treatment-resistance documentation. Domestic expanded-access remains the most practical option for many US veterans in 2026.
How Is the VA Approaching Psilocybin in 2026?
The Department of Veterans Affairs announced a nine-site clinical trial network for psilocybin-assisted therapy in veteran PTSD in 2024, with active enrollment continuing through 2025 and 2026 (VA Office of Research and Development, 2024). The trial network represents the largest federal commitment to psychedelic research for veteran mental health. Sites include several VA medical centers paired with academic medical center partners. The protocol uses synthetic psilocybin in supervised dosing sessions with preparation and integration support.
The VA approach matters for two reasons beyond the trial itself. First, it creates an infrastructure of trained clinicians inside the VA system who will be positioned to deliver care if and when FDA approval lands. Second, it generates outcome data in the specific veteran population that the eventual clinical guidelines will reference. The MAPP1 and MAPP2 MDMA data, while strong, did not enroll veteran-specifically. The VA psilocybin network is designed to fill that veteran-specific evidence gap, which is methodologically important for coverage decisions and clinical practice guidelines.
Enrollment in VA trials is competitive and the criteria are specific. Veterans interested in trial participation typically need a confirmed PTSD diagnosis, documented response failure to at least one first-line treatment, and willingness to complete pre-screening that includes cardiovascular and psychiatric evaluation. Bipolar disorder, psychotic disorder history, and certain cardiac conditions are typical exclusion criteria. The screening question matters more than most veterans initially realize. We've written separately about the importance of careful bipolar screening before any psychedelic protocol, which applies to both trial enrollment and any other access pathway.
"The VA network is the first time the federal system has committed clinical infrastructure to a Schedule I substance for veteran care. Whatever the FDA timeline turns out to be, the trained-clinician capacity is being built in parallel, not after."
How Do MDMA, Ibogaine, Psilocybin, and Ketamine Compare for Veterans?
The four substances with clinical evidence in veteran PTSD differ substantially in mechanism, evidence strength, access pathway, and cost. No single substance is optimal for every veteran's situation: MDMA has the deepest randomized controlled trial evidence base, ibogaine has the largest naturalistic veteran-specific effect sizes, psilocybin has the broadest access infrastructure and is the substance the VA is actively studying, and ketamine is the only legally accessible option in all 50 US states without travel. The comparison matrix below summarizes operational differences relevant to veteran decision-making in 2026.
| Substance | Strongest Evidence | Access Path in 2026 | Typical Cost | Veteran Considerations |
|---|---|---|---|---|
| MDMA | MAPP1 67%, MAPP2 71.2% no longer meeting PTSD criteria (Mitchell, 2021, 2023) | US expanded access, Australia TGA, Switzerland Section 8(5) | $15,000 to $40,000 full protocol | Most replicated PTSD evidence base; cardiac and SSRI screening required |
| Ibogaine | VETS 93.2% improvement, Stanford 88% remission (Davis, Cherian, 2024) | Mexico licensed clinics; Texas trial program forming | $8,000 to $20,000 single protocol | Largest naturalistic veteran-specific cohort; cardiac screening critical |
| Psilocybin | Multiple Phase 2 trials; VA nine-site trial network active | Oregon, Colorado, New Mexico, Australia; VA trials | $2,000 to $4,500 per session in Oregon | Broadest legal access; bipolar and psychotic disorder screening required |
| Ketamine | FDA-approved Spravato for treatment-resistant depression and suicidality | All 50 US states off-label; VA Spravato coverage in some sites | $400 to $800 per IV infusion | Most accessible legal option; six to eight sessions typical for PTSD protocols |
The matrix reveals what most coverage misses. If MDMA is the substance with the deepest evidence, the access pathway is not in fact the easiest, because of the FDA Complete Response Letter status. If ibogaine has the largest effect sizes, it is also the riskiest substance from a cardiac safety standpoint and requires the most careful pre-screening. Psilocybin offers the broadest legal access and is the substance most likely to land first inside the VA system. Ketamine, often dismissed by veterans seeking the more dramatic psychedelic experiences, remains the only legal option without travel and produces meaningful PTSD outcomes in many cases.
The MAPP2 Phase 3 trial of MDMA-assisted therapy for PTSD reported by Mitchell and colleagues in Nature Medicine in 2023 found that 71.2 percent of participants in the active arm no longer met PTSD diagnostic criteria at study endpoint, compared with 47.6 percent in the therapy-only control group, confirming the earlier MAPP1 trial finding of 67 percent remission (Mitchell et al., Nature Medicine, 2021, 2023). The replication was the key methodological step the FDA had requested before considering approval.
What Did the April 2026 Executive Order Actually Change?
The Trump administration's April 2026 executive order directed the FDA to establish an accelerated review pathway for psychedelic medicines with breakthrough-therapy designation, naming psilocybin, MDMA, and ibogaine specifically (whitehouse.gov, April 2026). The order instructed the VA to expand expanded-access infrastructure for veterans with treatment-resistant PTSD, and directed the Department of Defense to coordinate with the VA on psychedelic research for active-duty service members and veterans. The order did not approve any new substance, it accelerated the review framework.
The practical implication for veterans is mixed. The order does not create immediate new legal access pathways. It does signal a federal policy posture favorable to FDA action under the new framework. Texas allocated 50 million dollars in 2025 to fund ibogaine clinical trials, the largest state-level commitment to Schedule I substance research in US history. Kentucky has introduced similar legislation. The combination of state-level and federal-level alignment is the most favorable policy environment for veteran-focused psychedelic research since the early DEA scheduling decisions in the 1970s.
For veterans planning treatment in 2026, the policy environment is moving in a permissive direction, but FDA approvals are not in effect yet. Expanded-access programs, state-level psilocybin programs in Oregon, Colorado, and New Mexico, and international access in Australia and Switzerland remain the realistic legal pathways for the year. The VA trial network is the highest-quality and lowest-cost option for veterans who meet eligibility criteria, with treatment provided at no out-of-pocket cost in exchange for participation in the research protocol.
Regulatory status changes. The information in this article reflects clinical and policy status as of May 17, 2026 based on the named government sources and peer-reviewed publications. Before booking any session, traveling for treatment, or enrolling in a trial, verify current status with the trial coordinator, your VA care team, or qualified legal and medical counsel. This article is not medical or legal advice.
Why Do So Many Veterans Become Founders, and How Does That Change the Calculation?
A substantial portion of the founders I work with in integration have military backgrounds, and the post-service entrepreneurship pipeline is well-documented in Census Bureau small business ownership data. The veteran-to-founder transition is partly cultural (operators are trained to take ownership) and partly economic (transitioning service members often face structural employment friction that pushes toward self-employment). The psychological overlap matters here. The same nervous system patterns that operators bring to combat, vigilance, threat anticipation, hyper-arousal, do not switch off in a startup environment.
In 900+ integration sessions, the veteran-founder population has been a consistent presence and a consistent learning case. The pattern that shows up most often is residual hyper-arousal that operates as a performance asset in the early launch phase and becomes a liability later. Veterans who run founders often report functioning extremely well in acute startup phases, then encountering the same nervous-system dysregulation that pre-existed the military service, after the company stabilizes. The psychedelic conversation often arrives at this stage, when the structural validity of the trauma response is no longer obvious from the current life context.
The substance choice for veteran-founders depends on whether the dominant target is the trauma signature itself or the performance-related stress accumulation. MDMA-assisted therapy for complex PTSD in founders is the deepest evidence base for the trauma signature. Ibogaine integration is the relevant frame for veterans choosing the Mexico pathway and needing structured re-entry support. Psilocybin in Oregon or Colorado offers broader exploratory utility. Ketamine offers the lowest-friction local option for those with calendar constraints. The combination of trauma-specific work plus performance integration is rarely a single-substance, single-session question.
The screening considerations apply with particular force in this population. Cardiac status, psychiatric history including any prior manic episodes, current medications, and traumatic brain injury history all affect substance choice. The veteran-founder profile sometimes includes blast exposure or TBI that the founder has minimized or normalized. This matters for ibogaine in particular and shapes the protocol selection in any pathway. Pre-screening is not a barrier, it is the structure that makes the session safe and the integration possible.